Cell expression system

ABSTRACT

An expression system for expressing a protein comprising: a eukaryotic host cell carrying a dihydrofolate reductase (DHFR) deficiency; and an expression vector, the expression vector encoding the human growth hormone gene; a expression vector, the expression vector comprising: a eukaryotic selectable marker including a minimal SV 40 early promoter driving expression of a sequence encoding dihydrofolate reductase for complementing the DHFR deficiency in the host cell; a prokaryotic selectable marker conveying Ampicillin resistance to a prokaryotic host cell; a prokaryotic Origin of Replication; a plurality of multiple cloning sites (MCS); and at least one protein expression module comprising: a Simian Vacuolating Virus 40 (SV40) early promoter, inclusive of its 72 bp enhancer repeats; and a rabbit β-globin intron sequence being separable from a SV40 p A sequence by a first multiple cloning site, for receiving a coding sequence and expressing a desired protein therefrom.

TECHNICAL FIELD

The present invention relates to expression systems, in particular theinvention relates to expression systems for the production of biologicaltherapeutics.

BACKGROUND

Expression systems for the production of biological therapeutics orbiopharmaceuticals, such as recombinant proteins, generally consist of anucleic acid vector construct encoding the desired recombinanttherapeutic and a chosen host cell. The vector is introduced into thehost cell and the endogenous cell machinery is utilised for theproduction of the desired therapeutic i.e. the desired recombinantprotein. The intricacies in establishing an efficient and reliableexpression system for the production of approvable biologicaltherapeutics are manifold. However, well-established expression systemsmay provide cost-effective alternatives for the production ofpharmaceutical products otherwise difficult to obtain.

Efficiency of the system itself depends on a large variety of factorsincluding the design of the vector and the choice of host cell. Thestrategic combination of regulatory elements, selection markers andstability elements within the vector sequence have to balance simplemanipulation and application of the vector with high yield production ofthe desired biological therapeutic. Determining a cell's suitability toact as host cell in such an expression system is primarily governed bythe need to maximise compatibility between the endogenous cell machineryand the regulatory elements present in the vector, while keepingpotential adventitious contaminants in the final product minimal.Further, availability, cost and acceptability for regulatory approval ofany therapeutic produced by the system, have to be considered.

Nucleic acid vectors used in expression systems comprise plasmids,cosmids, Yeast Artificial Chromosomes (YACs), Bacterial ArtificialChromosomes (BACs), retroviral, adenoviral and lentiviral vectors. Thesevectors differ in many characteristics, such as their capacity toaccommodate different sized nucleic acid inserts, their most efficientintroduction method into the host cell and specifically in theirutilisation of the endogenous cell machineries of different types ofhost cells to ensure sufficient expression of the desired protein.

Regulatory elements commonly present in such expression vectorsinfluence transcription, translation as well as protein synthesis ofselection markers and of sequences encoding the desired biologicaltherapeutic. Such regulatory elements include, but are not limited to,promoters, terminators, modifiers, insulators, spacers, regulatoryprotein binding sites, introns, inducers, etc.

Known promoters include constitutively active promoters such as thethymidine kinase (TK) promoter, the actin promoter, the glyceraldehyde3-phosphate dehydrogenase (GAPDH) promoter, the simian vacuolating virus40 (SV40) early promoter, the cyclin T1 promoter, the RNA polymerase IIIU3 promoter, the cyclophillin promoter, the cytomegalovirus (CMV)promoter, the Autographa californica nuclear polyhedrosis virus (AcNPV)P10 promoter and the β3-galactosyltransferase 5 (β3GAL-T5) promoter.

Known promoters also include inducible promoters such as the heat shockprotein 70 (HSP70) promoter (stress induced), the heat shock protein 90(HSP90) promoter (stress induced), the alcoholdehydrogenase I (alcA)promoter (alcohol induced), the activating copper-metallothioneinexpression (ACE1) promoter (metal induced), the small subunit ofribulose-1,5-bisphophate-carboxylase (SSU1) promoter (light induced),the hypoxia induced factor 1α (hif1α) promoter (hypoxia induced), theinducer of meiosis 2 (IME2) promoter (starvation induced), theglucocorticoid receptor (hormone induced), the estrogen receptor(hormone induced) and the ecdysone receptor (hormone induced).

Further, cell type/tissue specific promoters, such as the nkx2.5promoter (heart cells), the islet 1 promoter (pancreatic cells), theMyoD promoter (muscle cells), the cluster of differentiation 2 (CD2)promoter (T-cells) and the collagen II promoter (cartilage), are knownto change their level of activity in response to cell type specificstimuli or to progression through developmental stages.

Known terminator elements, such as the RNA Polymerase II terminator, thesmall nucleolar RNA 13 (snR13) terminator, the bovine growth hormone(BGH) terminator, the simian virus 40 (SV 40) terminator and thethymidine kinase (TK) terminator, may provide suitable polyadenylationsignals.

Known modifier and insulator elements include the tetracyclineoperator/receptor (tetO/tetR) system, the upstream activating sequenceof the galactose dependent GAL4 transcription factor (GAL4 UAS), theadenovirus early region B1 TATA box, binding sites for the herpessimplex virus (HSV) regulatory protein VP16, the 5′HS4 chicken β-globininsulator, the paternally expressed gene 3 (Peg3) insulator and the seaurchin arylsulfatase (ARS) gene insulator.

While many attempts have been made to establish efficient and reliableexpression systems for the production of approvable biologicaltherapeutics, problems relating to low yield and adventitiouscontamination of the produced biopharmaceuticals remain. Choosing themost effective combination of suitable regulatory elements from theplethora of options, such that the system conveys stability and thehighest degree of compatibility with the endogenous host cell machinery,poses a major challenge in the field.

Obtaining regulatory approval for a biopharmaceutical product poses afurther challenge. Regulatory approval involves determination of thesafety and efficacy of the pharmaceutical product prior to marketing.The process of gaining regulatory approval for innovator drugs is verytime consuming and expensive. However, once approved, these drugs may bevery profitable, particularly when they are marketed under exclusivityrights such as patent protection.

The profitability of innovator drug's market may provide a substantialincentive to exploit this market once patent rights have expired.Following patent expiry, innovator drugs can be marketed as genericdrugs or biosimilars for drugs produced by recombinant DNA technology.Generic versions of blockbuster biopharmaceuticals near patent expiryinclude Epogen (erythropoietin, EPO) and Neupogen (granulocyte colonystimulating factor, G-CSF). The approval of a follow-on version ofPfizer's Genotropin (recombinant human growth hormone) seems to indicatea change in a landscape where previously, biopharmaceuticals enjoyedimmunity from competition even after expiration of their patentprotection. At present, there are over 80 generic versions ofbiopharmaceuticals in development (Datamonitor 2010).

Biosimilars ideally are bioequivalents of the innovator drugs and, assuch, the path to regulatory approval for biosimilars is in theory lessarduous than for the original innovator drug as the clinical dataestablishing safety and efficacy have been carried out.

Approval of generic biopharmaceuticals is dependent on comparable dosageform, strength, route of administration, quality, performancecharacteristics and intended use compared with approvedbiopharmaceuticals (that is, the reference listed drugs). For example,under the United States Food and Drug Administration (FDA), approval fora generic drug involves an “Abbreviated New Drug Application” (ANDA)which generally does not include pre-clinical and clinical data toestablish safety and effectiveness. Approval also involves abioequivalence review, which establishes that the proposed generic drugis bioequivalent to the reference-listed drug. This bioequivalency isbased upon a demonstration that the rate and extent of absorption of theactive ingredient in the generic drug fall within the scope of theparameter of the reference listed drug.

Importantly, there is a chemistry/microbiology review process thatprovides an assurance that the generic drug will be manufactured in areproducible manner under controlled conditions to ensure that the drugwill perform in a safe and acceptable manner.

Although guidelines for the approval of biosimilar drugs exist, there isuncertainty in regard to the practicalities of regulatory approval ofbiosimilars. Much of the uncertainty is driven by the lack of a clearpractical and detailed regulatory pathway for the approval of such drugsand the scientific debate over product comparability andinterchangeability. The uncertainties resulting from the manufacture ofbiosimilar drugs under conditions different than those used by theinnovator suggest that it may be impossible to develop a true “generic”version of a biotechnology drug. Indeed, regulatory authorities inEurope and the US have shunned the use of the term “biogeneric”,preferring the nomenclature “biosimilar” and “follow-on biologicals”.

Many quality concerns for expression system-derived biopharmaceuticalshave originated from the presence of adventitious contaminants or fromthe properties of the host cells used to prepare the product. Several ofthese products have also had quality concerns regarding the expressionvector of the system. It is well established that cell properties andevents linked to cell culture can affect resultant product quality andsafety. Effective quality control of recombinant products requiresappropriate controls on all aspects of handling the cell and cellculture. This is particularly relevant to the development ofbiosimilars.

Previously, Chinese Hamster Ovary (CHO) cells were modified andengineered to produce insulin. However these CHO cells were unable toexpress biological active insulin and thus the patents associated withthis type or method of CHO cell modification were not commercialexploited. Fully functional insulin was not produced in CHO cells due tocryptic splicing of the insulin gene message by the translationalmachinery In the CHO cell.

Any discussion of the prior art throughout the specification should inno way be considered as an admission that such prior art is widely knownor forms part of common general knowledge in the field.

It is an object of the present invention to overcome or ameliorate atleast one of the disadvantages of the prior art, or to provide a usefulalternative.

SUMMARY Means for Solving the Problem

A first aspect of the present invention may relates to novel expressionsystems and methods of employing an expression system according to theinvention that may, in certain embodiments, increase the yield anddecrease the cost of manufacture.

This invention relates to methods of production of recombinantbiosimilars, bio-pharmaceuticals and other desirable proteins,polypeptides and peptides using mammalian cell cultures. In particular,the methods of the invention involve the use of specially bioengineeredmammalian cell lines for the production of complex proteins in low costmedia. These cell lines have the acquired ability for autonomous growthin cheap, reproducible, fully-defined protein-free medium, with thecells expressing and secreting its growth factor requirements.

Accordingly, in a first aspect, the present invention provides anexpression system for expressing a protein comprising:

a eukaryotic host cell carrying a dihydrofolate reductase (DHFR)deficiencyan expression vector, the expression vector encoding the human growthhormone gene;an expression vector, the expression vector comprising:a eukaryotic selectable marker downstream of for expression of asequence encoding dihydrofolate reductase for complementing the DHFRdeficiency in the host cell;a prokaryotic selectable marker conveying Ampicillin resistance to aprokaryotic host cell;a prokaryotic Origin of Replicationa plurality of multiple cloning sites (MCS); andat least one protein expression module comprising:a Simian Vacuolating Virus 40 (SV40) early promoter, inclusive of its 72bp enhancer repeats; and a rabbit β-globin intron sequence beingseparable from a SV40 polyadenylation sequence by a first multiplecloning site, for receiving a coding sequence and expressing a desiredprotein therefrom.

Preferably, the expression system further comprises a second proteinexpression module, the second protein expression module including: aCyotomegalovirus promoter being separable from a SV40 polyadenylationsequence by a second multiple cloning site for co-expression of at leasttwo proteins from the expression modules.

Preferably, the protein is the subject of a request for regulatoryapproval and wherein the host cell is subjected to a plurality ofpredetermined manipulations such that the host cell expresses saidprotein; and wherein information is recorded on each manipulation andeach manipulation is carried out in a manner which prevents contact ofthe host cell with a contaminating agent; and wherein the information isused to generate a history record of the host cell for inclusion in asubmission to a regulatory agency involved in assessing the safety andefficacy of drugs thereby expediting regulatory approval of the protein.

The predetermined manipulations preferably comprise:

-   -   (i) ligating the coding sequence encoding the desired protein        into the expression vector to produce a recombinant vector;    -   (ii) introducing the recombinant vector into the host cell; and    -   (iii) culturing the host cell under conditions such that the        protein is expressed by the host cell.

Preferably the recombinant vector is at least in part incorporated intothe genome of the host cell. Step (iii) includes growing the host cellin a medium that contains no animal or plant derived proteins orpeptides and no undefined hydolysates or lysates thereby reducingcontact of the host cell with a contaminating agent.

In a particularly preferred embodiment, the host cell is a ChineseHamster Ovary (CHO) DG44 cell.

In certain preferred embodiments, the host CHO DG44 expresses a growthhormone. In certain preferred embodiment the growth hormone is humangrowth hormone. In certain preferred embodiments, the protein may be abiosimilar drug.

In a second aspect, the present invention provides a method of managingthe development of a protein expressed by the expression systemaccording to the first aspect wherein the protein is the subject of arequest for regulatory approval, the method comprising the steps of:

-   -   a. subjecting the host cell to a plurality of predetermined        manipulations such that the cell expresses the protein;    -   b. recording information on each manipulation wherein each        manipulation is carried out in a manner which prevents contact        of the host cell with a contaminating agent;    -   c. using the information to generate a history record of the        host cell for inclusion in a submission to a regulatory agency        involved in assessing the safety and efficacy of drugs; and    -   d. including the history record in the submission to the        regulatory agency for regulatory approval of the product.

In a third aspect, the present invention provides a method of expeditingregulatory approval of a protein expressed by the expression systemaccording to the first aspect the method comprising:

-   -   b. subjecting the host cell to a plurality of predetermined        manipulations such that the host cell expresses the product;    -   c. recording information on each manipulation wherein each        manipulation is carried out in a manner which prevents contact        of the host cell with a contaminating agent;    -   d. using the information to generate a history record of the        host cell for inclusion in a submission to a regulatory agency        involved in assessing the safety and efficacy of drugs; and    -   e. including the history record in the submission to the        regulatory agency for regulatory approval of the protein.

Preferably, step (a) of the methods according to the second and thirdaspect comprises

-   -   (i) ligating the coding sequence encoding the desired protein        into the expression vector to produce a recombinant vector;    -   (ii) introducing the recombinant vector into the host cell; and    -   (iii) culturing the host cell under conditions such that the        protein is expressed by the host cell.

The recombinant vector is preferably at least in part incorporated intothe genome of the host cell.

Preferably, step (iii) of the methods according to the second and thirdaspect includes growing the host cell in a medium that contains noanimal or plant derived proteins or peptides and no undefinedhydrolysates or lysates thereby reducing contact of the host cell with acontaminating agent.

In a particularly preferred embodiment of the methods according to thesecond and third aspect, the protein is a biosimilar drug.

Another aspect of the present invention may also provide a method forproducing a desired recombinant protein, polypeptide or peptidecomprising the step of: culturing a mammalian host cell in culturemedium, wherein said host cell includes:

-   (i) at least one introduced DNA sequence encoding a protein,    polypeptide and/or peptide factor(s) required for growth of the host    cell in said culture medium, expressibly linked to a constitutive    promoter (e.g. CMV and SV40 promoters) The invention thereby enables    the use of low cost, protein/serum-free medium by utilising a host    cell which is able to produce the protein, polypeptide and/or    peptide growth factor(s) required for its growth in such medium. The    culture medium used in the method of the invention is, therefore,    preferably serum-free or otherwise free of protein, polypeptide    and/or peptide growth factor(s) necessary for the growth of the    particular host cell type. However, methods wherein the culture    medium includes one or more of the required growth factor(s) and the    host cell itself expresses one or more of the same and/or other    required growth factor(s), is also to be regarded as falling within    the scope of the invention.

The mammalian host cell may be any of those commonly used in the art forexpressing recombinant proteins, polypeptides or peptides. For example,the host cell may be a Chinese Hamster Ovary (CHO) cell such as CHO-K1,CHO-DG44 DHFR- and CHO-S. These include both adherent and suspensioncell lines. Also other cell lines described within the embodiments ofthe present invention may also be used or preferred.

The introduced DNA sequence(s) may be present on plasmids or otherwiseintegrated into the host cell chromosomes (e.g. by homologousrecombination).

The DNA sequence(s) encoding the protein, polypeptide and/or peptidefactor(s) required for growth of the host cell, may be selected from DNAsequences encoding human Growth Hormone (hGH), modified hGH and othergrowth factors and mixtures thereof. Where the host cell is CHO it ispreferable that the host cell includes DNA sequences encoding humanGrowth Hormone (hGH).

In the context of the present invention, the words “comprise”,“comprising” and the like are to be construed in their inclusive, asopposed to their exclusive, sense, that is in the sense of “including,but not limited to”.

In the context of the present invention, the words “comprise”,“comprising” and the like are to be construed in their inclusive, asopposed to their exclusive, sense, that is in the sense of “including,but not limited to”.

The invention is to be interpreted with reference to the at least one ofthe technical problems described or affiliated with the background art.The present aims to solve or ameliorate at least one of the technicalproblems and this may result in one or more advantageous effects asdefined by this specification and described in detail with reference tothe preferred embodiments of the present invention.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A is a plasmid vector map entitled “pNAS-hGH” for the high levelexpression human growth hormone (hGH) inserted within a pNAS vector withuse with NeuCHO cell line;

FIG. 1B is an expression vector map entitled “pNeu” used for the highlevel expression of a single chain protein in CHO DG44 cells;

FIG. 1C is an expression vector map entitled “pNeu-IRES-DHFR” used forthe high level expression of a single chain protein in CHO DG44 cells. Adicistronic expression cassette with recombinant gene in 1^(st) cistronfollowed by DHFR gene in 2^(nd) cistron;

FIG. 1D is an expression vector map entitled “pNeuMAB” used for the highlevel expression of heavy and light antibody chains and/or recombinantmonoclonal antibodies;

FIG. 1E is an expression vector map entitled “pNeuMAB-IRES-DHFR” usedfor the high level expression of heavy and light antibody chains;

FIG. 1F is an expression vector map entitled “pNeuMAB-IRES-DHFR (CMV)”used for the high level expression of heavy and light antibody chains;

FIG. 1G is a single chain expression vector map entitled “pMAB LC(IRES-DHFR)” used for expression of light chains (LC);

FIG. 1H is a single chain expression vector map entitled “pMAB HC” usedfor expression of heavy chains (HC);

FIG. 2. depicts a growth chart demonstrating viable cell density plottedagainst time in respect of various cultures and cells used. Growth ofDG44 Cell Lines expressing hGH compared to the Parental DG44 Cell Lineand a DG44 Cell Line expressing the IGF-1 gene;

FIG. 3. depicts a graph comparing the integral of viable cell densitiesagainst time for various preferred organisms and culture; and

FIG. 4. depicts a comparison chart showing the relative expressionlevels of proteins from either CHO DG44 cells or NeuCHO cell lines.

This specification also includes the following genetic sequenceinformation relating to expression vectors:

Sequence No. 1 depicts the preferred coding sequence for the expressionvector pMAB HC;

Sequence No. 2 depicts the preferred coding sequence for the expressionvector pMAB LC(ires-dhfr);

Sequence No. 3 depicts the preferred coding sequence for the expressionvector pNAS-hGH;

Sequence No. 4 depicts the preferred coding sequence for the expressionvector pNeu;

Sequence No. 5 depicts the preferred coding sequence for the expressionvector pNeu-IRES-DHFR;

Sequence No. 6 depicts the preferred coding sequence for the expressionvector pNeuMAB;

Sequence No. 7 depicts the preferred coding sequence for the expressionvector pNeuMAB-IRES-DHFR (CMV);

Sequence 8 depicts the preferred coding sequence for the expressionvector pNeuMAB-IRES-DHFR;

Please note that in this specification Sequence No. is same and theequivalent term to SEQ ID NO.

DESCRIPTION OF THE INVENTION

Preferred embodiments of the invention will now be described withreference to the accompanying drawings and non-limiting examples.

It has been found that events during the culture of a cell maycontribute significantly to the assessment of the risks associated withthe use of that particular cell for production of proteins and moreparticularly proteins for therapeutic use.

Diligent records of all manipulations including the history of a cellthroughout development, extending to the parental cell line from whichit was derived, may contribute to the quality and safety of the finalproduct.

In one scenario, such information may be important for gainingregulatory approval of protein therapeutics expressed from a cell. Inparticular, biosimilars present unique issues. These issues includedemonstrating that immunogenicity of the biosimilar has not been alteredwith respect to the reference listed drug, as well as ensuring thatthere are no undetected differences in the product that may potentiallyimpact the safety and efficacy of the drug. Resolving such issues wouldbe problematic without conducting extensive clinical trials. As such, itis likely that any application for a biosimilar would be required todemonstrate that there are no clinically meaningful differences insafety, purity and potency between the biosimilar and the referencelisted drug. Moreover, an application for a biosimilar would need toprovide evidence that the biosimilar has “profound similarity” (as it isimpractical to demonstrate identical biological products) and that thebiosimilar will produce the same clinical result as the reference listeddrug in any given patient.

In order to gain regulatory approval, traditional generic manufacturersare required to demonstrate their drug is chemically identical to thereferenced listed drug and exhibit the same properties in the human bodyas the original drug. In regard to biosimilars, it was previously notpossible to readily demonstrate that a second-source biologic drug isunequivocally identical to an innovator drug due to the complexities ofthe synthesis of the drugs in potentially disparate biological systems.As such, biosimilars may exhibit slightly different properties to theoriginal drugs that may necessitate abbreviated clinical trials in orderto gain regulatory approval.

In the context of the present invention, the term “contaminating agent”refers to any agent that can potentially compromise regulatory approvalof a product by a regulatory agency. Such agents may include but are notlimited to adventitious agents such as viruses, bacteria, fungi andmycoplasma or proteins there from.

As used herein the term “cell expressed product” refers to any productproduced by the cell, including but not limited to proteins, peptides,glycoproteins, carbohydrates, lipids, glycolipids and nucleic acids.

The term “regulatory approval” in so far as it relates to a productdefined in the context of this specification, refers to approval from aregulatory authority which permits marketing of the product.

The term “safety and effectiveness studies” refers to any studiesconducted on a product that assess the safety and efficacy of thatproduct for human and/or animal administration.

The term “clinical trials” refers to studies involving either animal orhumans designed assess the safety and/or efficacy of a product for atherapeutic application.

The term “abbreviated safety effectiveness studies and/or abbreviatedclinical trials” refers to studies carried out on a drug which does notinvolve complete phase I, II and III clinical trials. Such studies mayinclude a bioequivalence review and a chemistry/microbiology review asdefined by the US Food and Drug Administration (FDA).

The term “biosimilar drug” and “biosimilar” refer to a bioequivalentpharmaceutical of a drug in which patent protection has expired andwhere the previously protected drug has regulatory approval. Inparticular, this includes products prepared in cell culture byrecombinant DNA technology. The term “biosimilar drug” and “biosimilar”as used herein is equivalent to the terms “follow-on biologicals” or“biosimilars”.

The term “protein” refers to a “complete” protein as well as fragments,derivatives or homologs or chimeras thereof comprising one or more aminoacid additions, deletions or substitutions, but which substantiallyretain the biological activity of the complete protein.

The embodiments of the present invention will now be described byreference to the following non-limiting examples.

Example 1 Construction of pNeu and pNAS Vectors for High LevelExpression of Recombinant Therapeutic Protein

The vector pNeu was designed for high-level expression of single chainpeptides for the production of therapeutic proteins. The vectorfacilitates the insertion DNA sequences into a convenient multiplecloning site for expression in CHO cells. See Table 1 and FIG. 1A for adescription of the vector and its component features.

The 5026 bp vector encodes essential coding and regulatory sequences forthe efficient expression of the recombinant gene as well as essentialsequences for the selection and propagation of the plasmid in bacteria.It was designed for chemical synthesis and is void of nonessential andredundant sequences that are common components in commercial expressionvectors. This allows for ease of genomic insertion with less likelihoodof deletion of sequences during plasmid propagation resulting in loss ofexpression. The multiple cloning site encodes a minimum of two uniquerestriction sites for rapid gene cloning.

Example 2 Synthesis and Cloning of Human Growth Hormone (hGH) cDNA intopNAS

The amino acid sequence encoding for hGH was subjected to bioinformaticanalysis through proprietary third party software by GENEART AG,Regensburg Germany. Codon options were utilized to maximize expressionby improving mRNA maintenance and the exploitation of available tRNApools in CHO cells. RNA and codon optimization was performed on thecoding sequences. The gene was analysed with respect to splice siterecognition, mRNA stability, presence of ribosomal entry sites, mRNAsecondary structures, self-homology for the purpose of increasing geneexpression in CHO cells. The hGH gene was cloned into pNAS using AgeIand EcoRV restriction sites using methods well known in the art.

Example 3 Construction of pNeuMAB Vector for Expression of RecombinantMonoclonal Antibody

The pNeuMAB vector was designed for the cloning and expression ofrecombinant monoclonal antibodies. The DNA encoding heavy and lightchains are configured in the vector as two distinct and tandemtranscription units. See Table 1 and FIG. 1B for a description of thevector and its component features.

Synthesis of cDNA Encoding Heavy Chain and Light Chain of anAntibody—Infliximab

The amino acid sequence encoding the heavy chain (HC) and light chain(LC) of the monoclonal antibody, Infliximab were subjected tobioinformatic analysis through proprietary third party software byGENEART AG, Regensburg Germany. Codon options were utilized to maximizeexpression by improving mRNA maintenance and the exploitation ofavailable tRNA pools in CHO cells. RNA and codon optimization wasperformed on the coding sequences. The genes were analysed with respectto splice site recognition, mRNA stability, presence of ribosomal entrysites, mRNA secondary structures, self-homology for the purpose ofincreasing gene expression in CHO cells.

Cloning Gene Encoding Heavy Chain of Infliximab

The synthetic gene encoding for the heavy chain of Infliximab wasassembled from synthetic oligonucleotides and/or PCR products. Thefragment was cloned into pGA14 (ampR) using AscI and Pad restrictionsites. The plasmid DNA was purified (Pure Yield™ Plasmid Midiprep,Promega) from transformed bacteria and concentration determined by UVspectroscopy. The final construct was verified by sequencing. Thesequence congruence within the used restriction sites was 100%. Thesynthetic cDNA sequence encoding heavy chain of Infliximab was designedto incorporate unique restriction sites Age I and Eco RV at the 5′ and3′ ends respectively for directional cloning into the first multiplecloning site of NeuClone's antibody expression vector, pNeuMAB digestedwith the same restriction sites.

Cloning Gene Encoding Light Chain of Infliximab

The synthetic gene encoding the light chain of Infliximab was assembledfrom synthetic oligonucleotides and/or PCR products. The fragment wascloned into pGA18 (ampR) using AscI and Pad restriction sites. Theplasmid DNA was purified (Pure Yield™ Plasmid Midiprep, Promega) fromtransformed bacteria and concentration determined by UV spectroscopy.The final construct was verified by sequencing. The sequence congruencewithin the used restriction sites was 100%. The synthetic cDNA sequenceencoding light chain of Infliximab incorporates the unique restrictionsites Sal I and Mlu I at the 5′ and 3′ ends respectively for directionalcloning into the second multiple cloning site of NeuClone's antibodyexpression vector, pNeuMAB digested with the same restriction sites.

Generation of NeuCHO

Transfection of DG44 Cells with pNAS-hGH

One of the preferred methods by which the expression vector encodinghuman growth hormone into the host CHO DG44 cell line and the status ofthe rDNA within the host (copy number, etc.) is as follows. Briefly, atotal of 1.5×10e7 cells were transfected with 1.8 ug of linearizedplasmid DNA together with 15 ul of FreeStyle MAX Reagent (Invitrogen) ina volume of 30 ml. The transfected cell cultures were incubated at 37 C,8% CO2 on an orbital shaker platform. At 48 hours post transfection thecells were cultured in hypoxanthine- and thymidine-deficient, mediumsupplemented with Gentamycin at a final concentration of 500 ug/ml forselection of uptake of plasmid DNA. Clones were selected by limitingdilution cloning. Several single clones arising from a single cell wereexpanded and cell lines were characterised for production of humangrowth hormone. Resulting clones were examined for growth properties incomparison to the standard CHO DG44 cell line.

Transfection of NeuCHO with pNeuMAB Encoding Infliximab Genes

Linearized plasmid pNeuMAB DNA encoding Infliximab genes was used totransfect NeuCHO cell cultures At 48 hours post transfection the cellswere cultured into hypoxanthine- and thymidine-deficient, medium toselect for cells expressing the DHFR gene. A stable cell population wasthen subjected to subsequent stepwise increasing methotrexate (MTX)concentration (50-, 100-, 200-, 400-, 800 nM, 1 uM) in order to amplifytemplate DNA copy number and gene expression. Clones were selected bylimiting dilution cloning. Clones with high level expression ofinfliximab protein were scaled up for protein production.

Example 4 Cell Banking

A critical part of quality control involves the full characterization ofcells. The cell banks are examined for adventitious agents (viral,bacterial, fungal and mycoplasmal). Documentation describing the type ofbanking system used, the size of the cell bank(s) the container (vials,ampoules and closure system used, the methods used for preparation ofthe cell bank(s) including the cryoprotectants and media used, and theconditions employed for cryopreservation and storage are provides.

The procedures used to avoid microbial contamination andcross-contamination by other cell types present in the laboratory, andthe procedures that allow the cell bank containers to be traced are allmade available. This includes a description of the documentation systemas well as that of a labelling system which can withstand the process ofpreservation, storage, and recovery from storage without loss oflabelling information on the container.

It is essential that production is based on a well-defined master andworking cell bank system. During the establishment of the banks no othercell lines are handled simultaneously in the same laboratory suite or bythe same persons. The origin, form, storage, use and expected durationat the anticipated rate of use are described in full for all cell banks.

The following table identifies some of the components and features ofthe various expression vectors using with either CHO DG44 or NeuCHO celllines. The data has been divided into three tables for purposes ofpresentation in this patent specification.

TABLE 1 pNeu-IRES- Feature pNeu DHFR pNAS pNeuMAB Multiple One multipleOne multiple One multiple Two multiple cloning site cloning site forcloning site for cloning site for cloning sites for insertion ofinsertion of insertion of insertion of expression unit expression unitexpression unit expression units coding for coding for coding for codingfor heavy single chain single chain single chain and light chainsprotein protein protein of a monoclonal antibody Strong The SV40 TheSV40 The CMV early The SV40 virus promoter/ virus early virus earlypromoter/ early enhancer promoter/ promoter/ enhancer drives promoter/combination enhancer enhancer expression of enhancer drives eachexpression of transcription the first and 2nd unit transcription unitIntron/ The intron The intron The intron intervening sequence IIsequence II sequence II from sequence from rabbit from rabbit rabbitbeta beta globin beta globin globin gene is gene is located gene islocated located downstream of downstream of downstream of the promoterthe promoter the promoter providing for providing for providing forincreased increased increased expression and expression and expressionand mRNA mRNA mRNA stability stability of the stability of the of thefirst transcription transcription transcription unit unit unit IntenalFor the Ribosome expression of Entry Site DHFR gene (IRES) downstream of2^(nd) transcription unit ensuring high level expression of 2^(nd)cistron in cells growing in the presence of methotrexate PolyadenylationA strong A strong A strong A strong signal polyadenylationpolyadenylation polyadenylation polyadenylation signal from signal fromsignal from S40 signal from S40 S40 virus for S40 virus for virus forvirus is for efficient efficient efficient efficient expression ofexpression of expression of expression of recombinant recombinantrecombinant each gene. gene. gene recombinant gene DHFR gene AuxotrophicAuxotrophic Auxotrophic selection in HT selection in HT selection in HTnegative media negative media negative media eliminates the eliminatesthe eliminates the need to need to need to maintain maintain maintainselection selection selection pressure using pressure using pressureusing antibiotics. antibiotics. antibiotics. Amplification ofAmplification Amplification gene copy of gene copy of gene copy numberis number is number is accomplished by accomplished accomplished theaddition of by the addition by the addition methotrexate to of of theculture methotrexate methotrexate media. The to the culture to theculture murine DHFR media. The media. The gene is driven murine DHFRmurine DHFR by a minimal gene is driven gene is driven SV40 early by aminimal by a minimal promoter SV40 early SV40 early lacking the promoterpromoter enhancer lacking the lacking the sequence enhancer enhancersequence. sequence. Ampicillin For For For propagation For propagationresistance propagation of propagation of of plasmid in of plasmid ingene plasmid in plasmid in bacteria bacteria bacteria bacteria NeomycinFor selection in gene mammalian cells

TABLE 2 pNeuMAB- pNeuMAB-IRES- pMAB-LC (ires- Features IRES-DHFRDHFR(CMV) dhfr) Multiple cloning Two multiple Two multiple One multiplecloning site cloning sites for cloning sites for site for insertion ofinsertion of insertion of Light chain gene expression units expressionunits coding for heavy coding for heavy and light chains and lightchains of of a monoclonal a monoclonal antibody antibody Strong The SV40virus The SV40 virus The SV40 virus early promoter/enhancer early earlypromoter/enhancer combination promoter/enhancer promoter/enhancer drivesexpression of drives drives expression LC gene expression of the of thefirst gene first and 2nd and the CMV genes promoter drives expression ofthe 2^(nd) gene. Intron/intervening The intron The intron The intronsequence II sequence sequence II from sequence II from from rabbit betarabbit beta globin rabbit beta globin globin gene is located gene islocated gene is located downstream of the downstream of downstream ofthe promoter providing the promoter promoter providing for increasedproviding for for increased expression and mRNA increased expression andstability of the expression and mRNA stability of transcription unitmRNA stability the transcription of the unit transcription unit IntenalRibosome For the For the expression For the expression of Entry Site(IRES) expression of of DHFR gene DHFR gene DHFR gene downstream of2^(nd) downstream of 2^(nd) downstream of transcription unittranscription unit 2^(nd) transcription ensuring high level ensuringhigh level unit ensuring high expression of 2^(nd) expression of 2^(nd)level expression cistron in cells cistron in cells of 2^(nd) cistron ingrowing in the growing in the cells growing in presence of presence ofthe presence of methotrexate methotrexate methotrexate Polyadenylation Astrong A strong A strong signal polyadenylation polyadenylationpolyadenylation signal signal from S40 signal from S40 from S40 virusfor virus for efficient virus for efficient efficient expression ofexpression of expression of recombinant gene. recombinant recombinantgene. gene. DHFR gene Auxotrophic Auxotrophic Auxotrophic selectionselection in HT selection in HT in HT negative media negative medianegative media eliminates the need to eliminates the eliminates the needmaintain selection need to maintain to maintain pressure using selectionpressure selection pressure antibiotics. using antibiotics. usingantibiotics. Amplification of gene Amplification of Amplification ofcopy number is gene copy gene copy number accomplished by the number isis accomplished by addition of accomplished by the addition ofmethotrexate to the the addition of methotrexate to the culture media.The methotrexate to culture media. The murine DHFR gene is the culturemedia. murine DHFR gene driven by a minimal The murine is driven by aSV40 early promoter DHFR gene is minimal SV40 lacking the enhancerdriven by a early promoter sequence. minimal SV40 lacking the earlypromoter enhancer sequence. lacking the enhancer sequence. AmpicillinFor propagation For propagation of For propagation of resistance gene ofplasmid in plasmid in bacteria plasmid in bacteria bacteria Neomycingene

TABLE 3 Features pMAB-HC Multiple cloning site One multiple cloning sitefor insertion of Heavy chain gene. Vector is similar to pNAS Strongpromoter/enhancer The CMV early promoter/enhancer drives combinationexpression of heavy chain gene Intron/intervening sequence IntenalRibosome Entry Site (IRES) Polyadenylation signal A strongpolyadenylation signal from S40 virus for efficient expression ofrecombinant gene. DHFR gene Ampicillin resistance gene Neomycin gene Forselection in mammalian cells

FIG. 1 A-H depicts a series of expression vector map relevant toexpression using CHO DG44 cell lines or NeuCHO cell lines.

More specifically, FIG. 1A depicts an expression vector pNAS includinghGH coding sequence for use in constructing the NeuCHO Cell Line fromCHO DG44. Preferably, NeuCHO cell line is produced by the inclusion ofthe vector shown in FIG. 1A within a CHO-DG44 cell line. The geneticsequence for this expression vector has been submitted along with thisapplication and is designated SEQ. ID No. 1.

It is noted that CHO DG44 cell line includes a relatively and fragilecell line which inherently has issues and problems in regard to longterm viability, cell density and population stability.

In this preferred embodiment, the addition of hGH to the cell culturevector may lead to increases in cell density or production that werepreviously not realisable using previous techniques and sequences.Previously, growth factors such as IGF-1 and insulin were used tosupplement CHO cells (such as DG44). However these previous methods leadto disappointing results in terms of cell viability and/or survival. Inthe present embodiments, the addition of hGH coding sequences to CHOcells allows for the excretions by the CHO-DG44 cells of hGH. Thisexpression and secretion of hGH into the cell media leads to increase incell survival of CHO cells.

Further the expression of hGH may also improve the robustness of theNeuCHO cell line as compared to other CHO cell lines.

More specifically, the addition of hGH expressing sequences to CHO-DG44cells gave rise to a new cell line, NeuCHO cell line. The NeuCHO cellline may include any of the expression vectors described and shown inrespect to FIGS. 1 A-H.

The NeuCho cell line, deposited under the provisions of the BudapestTreaty with the Cell Bank Australia located at 214 Hawkesbury Rd,Westmead, NSW, 2145, Australia as of 4 Feb. 2013 and assigned accessionno. CBA20130024, as is particularly suitable for use in pharmaceuticalmanufacture as described within the present application.

Preferably, the CHO-DG44 cell line was transfected with the pNAS-hGHvector to produce the NeuCHO cell line. Possible transfection methodsinclude: standard methods described in the scientific literatureincluding: calcium phosphate precipitation, PEI, Electroporation andlipofaction. It is generally noted that previous teachings in the fieldhave often argued that it is preferred to deliver higher relative levelsof DNA to cells by transfection to get better results. However,transfection methods delivering more DNA into the cell do not generatemore stable or high producing cell lines, as the cell lines may becomeless stable and less robust.

FIG. 1B depicts an expression vector used for the expression of a singlechain protein in CHO DG44 cells. Preferably, the recombinant geneexpression may be driven by the SV40 early promoter/enhancer within thevector. The genetic sequence for this expression vector has beensubmitted along with this application and is designated SEQ. ID No. 2.

FIG. 1C depicts an expression vector used for the expression of a singlechain protein in CHO DG44 cells. Preferably, a dicistronic expressioncassette with a recombinant gene in the 1^(st) cistron followed by aDHFR gene in the 2^(nd) cistron is described in this example. The geneexpression in this vector is preferably driven by SV40 early promoter orenhancer. The genetic sequence for this expression vector has beensubmitted along with this application and is designated SEQ. ID No. 3.

FIG. 1D depicts a pNeuMAB, which is a dual expression vector containingtwo cloning cassettes to insert heavy and light chain genes into asingle vector. This expression vector has two gene expression cassettesfor the insertion of multiple recombinant genes. Each cassette includesan SV40 early promoter and downstream poly A sequence. Each gene isdriven by driven SV40 promoter without an enhancer sequence. Thisexpression vector is suitable for expression of light and heavy chainsexpression of the antibodies. The genetic sequence for this expressionvector has been submitted along with this application and is designatedSEQ. ID No. 4.

FIG. 1E depicts a further expression vector, pNeuMAB-IRES-DHFR, for highlevel expression of heavy and light chains of a recombinant monoclonalantibody on a single vector driven one SV40 promoter and enhancer. Thisexpression vector may be used for the expression of light and heavyantibody chains. This expression vector generally includes two geneexpression cassettes for insertion of recombinant genes. Each cassetteconsists of SV40 early promoter/enhancer and downstream poly A sequence.Heavy chain and light chain are inserted in 1st and 2nd cassettesrespectively. The 2nd cassette is dicistronic having light chainfollowed by DHFR downstream of IRES. The genetic sequence for thisexpression vector has been submitted along with this application and isdesignated SEQ. ID No. 5.

FIG. 1F depicts a further expression vector, pNeuMAB-IRES-DHFR-(CMV),for high level expression of heavy and light chains of recombinantmonoclonal antibody on a single vector driven by CMV and SV40 promotersof heavy and light chains of antibodies respectively. The DHFR gene isdriven by IRES downstream of light gene; for the expression of heavy andlight chains of antibody in opposite orientations with respect to eachother. Heavy chain is driven by CMV promoter whereas light chain isdriven by SV40 promoter/enhancer. Light chain and DHFR gene have adicistronic configuration with DHFR downstream of IRES. The geneticsequence for this expression vector has been submitted along with thisapplication and is designated SEQ. ID No. 6.

FIG. 1G depicts a further expression vector, pMAB-LC (ires-dhfr), forexpression of only light chains (LC) of antibodies. A discistroniccassette for cloning LC in 1st cistron and DHFR in 2nd cassettedownstream of IRES. The vector is used in co-transfection with pMAB HC,which is the expression vector shown in FIG. 1H. The genetic sequencefor this expression vector has been submitted along with thisapplication and is designated SEQ. ID No. 7.

FIG. 1H depicts a further expression vector, pMAB-HC, for expression ofonly heavy chain (HC) of antibodies. Both pMAB-LC and pMAb-HC areco-transfected for expression of complete antibody. The genetic sequencefor this expression vector has been submitted along with thisapplication and is designated SEQ. ID No. 8.

A further graph is shown in FIG. 2. The graph of FIG. 2 represents the:Growth of DG44 Cell Lines expressing IGF-1 or hGH compared to theParental DG44 Cell Line and a Mock Cell Line. A control (mock) cell lineis derived from the Parental Cell Line which has been stably transfectedwith a DNA plasmid containing the selection marker but without the GeneOf Interest (GOI).

The preferred NeuCHO Cell Line demonstrates superior growth advantagecompared to the original Parental DG44 Cell Line. In this example, thegrowth of NeuCHO cells demonstrates higher viable cell densities to thatof a DG44 Cell Line expressing the IGF-1 gene.

This graph shows that when DG44 cells express human Growth Hormone,(Line Graphs E and F), the cells have a very high Maximum Viable CellDensity (up to 425%) compared to the untransfected DG44 Parental CellLine, the Mock transfected Cell Line, and DG44 Cell Lines expressinghigh or Low IGF-1 protein.

The NeuCHO Cell Line has an Integral Cell Density of up to 3.67×10⁷cell/day/mL, which is 230% that of the Parental DG44 Cell Line, 1.57×10⁷cell/day/mL.

Also in FIG. 2, the Viable Cell Density is plotted on the Y-axis incells/mL, and the number of days in culture is plotted on the X-axis.Six line graphs are shown in the figure, namely line graph A, B, C, D, Eand F.

Line A represents the growth pattern of a parental DG44 cell line thatis not transfected with DNA.

Line B represents the growth pattern of a parental DG44 cell line thatwas transfected with a DNA plasmid containing the selection marker butwithout the Gene Of Interest (GOI).

Line C represents the growth pattern of a parental DG44 cell line thatwas stably transfected with a DNA plasmid containing both the selectionmarker and the Gene Of Interest (GOI). The GOI here is Insulin-likegrowth factor 1 (IGF-1).

Line D represents the growth pattern of a parental DG44 cell line thatwas stably transfected with a DNA plasmid containing both the selectionmarker and the Gene Of Interest (GOI). The GOI here is Insulin-likegrowth factor 1 (IGF-1).

Line E represents the growth pattern of a parental DG44 cell line thatwas stably transfected with a DNA plasmid containing both the selectionmarker and the Gene Of Interest (GOI). The GOI here is human GrowthHormone (hGH).

Line F represents the growth pattern of a parental DG44 cell line thatwas stably transfected with a DNA plasmid containing both the selectionmarker and the Gene Of Interest (GOI). The preferred GOI in this exampleis human Growth Hormone (hGH).

In FIG. 3, a further graph is depicted comparing the integral of viablecell densities (IVCD) of NeuCHO with the standard CHO DG44 cells. Thisfigure demonstrates the difference in the Integral of Viable CellDensities achieved with the parent cell line NeuCHO compared to parentalCHO.

The NeuCHO cell line is superior in growth capabilities and thistranslates into a more efficient production process which can minimizecosts by having higher productions rates, fewer production runs, thuslower productions costs, lower Cost of Goods (COGS).

Growth and productivity of NeuCHO cell line expressing a recombinantmAB.

The preferred NeuCHO cell line demonstrates high titre of mAB x comparedto traditional CHO expression system.

FIG. 5 demonstrates in graphical form that NeuCHO cells may have greaterstable transfection efficiency than CHO cells (such CHO DG44 cells).Cells (NeuCHO and CHO) were transfected with DNA encoding mAB ‘x’ priorto selection and single cell cloning from a stable pool. The data isshown in FIG. 5 and demonstrates that stable transfection of NeuCHOcells results in a greater number of clones with high productivity thanthat of standard CHO cells. The graph shows the levels of variousprotein expressed in relative quantities at a given time.

NeuCHO cells have an integral of viable cell density that is about 230%greater than CHO DG44 cell lines. CHO DG44 cell lines expressing insulinlike growth factor 1 (IGF-1) do not demonstrate the ability to grow tohigh cell densities as NeuCHO cell lines may generally achieved. NeuCHOcells have a generally greater transfection efficiency than CHO DG44cells. The survival rate of transfected NeuCHO cells is generallygreater then transfected CHO DG44 cells. Additionally, transfection ofNeuCHO cells may result in a greater number of clones with a higherproductivity than that of standard CHO DG44 cells.

Preferably, the expression system and vectors described herein may beable to allow or facilitate CHO cells such NeuCHO or CHO DG44 cells toproduce desired proteins suitable for pharmaceutical preparationincluding, but not limited to: Infliximab tumour necrosis factor(referred to as Remicab™); Adalimumab tumour necrosis factor (referredto as Humira™); Etanercept tumour necrosis factor (referred to asEnbrel™); Rituximab CD20 (referred to as Rituxan™ & MabThera™);Bevacizumab vascular endothelial growth factor (referred to asAvastin™); Trastuzumab HER2 (referred to as Herceptin™); Ranibizumabvascular endothelial growth factor (referred to as Lucentis™); Cetuximabepidermal growth factor receptor (referred as Erbitux™); Erythropoietinα; Interferon α—Pegylated interferon alfa-2a; Interferon α—Pegylatedinterferon alfa-2b and hGH.

NeuCHO cells when used as feeder layer may also increase efficiency ofsingle cell cloning. NeuCHO cells were seeded in single wells ofmicrotitre plates prior to single cell cloning of a stable transfectedpool. Secretion of human growth hormone secreted from NeuCHO cellsresults in an increased survival rate of single cells following LimitingDilution Cloning.

Although the invention has been described with reference to specificexamples, it will be appreciated by those skilled in the art that theinvention may be embodied in many other forms, in keeping with the broadprinciples and the spirit of the invention described herein.

The present invention and the described preferred embodimentsspecifically include at least one feature that is industrial applicable.

1. A method for producing a desired recombinant polypeptide comprisingculturing a mammalian host cell expressing a desired recombinantpolypeptide in the presence of a human Growth Hormone (hGH) or modifiedhGH, wherein expression of the hGH or modified hGH enhances survivaland/or cell density and/or cell viability of the mammalian host cellexpressing the desired recombinant polypeptide.
 2. The method accordingto claim 1, wherein the mammalian host cell co-expresses the humanGrowth Hormone (hGH) or modified hGH and the desired recombinantpolypeptide.
 3. The method according to claim 1, wherein the hGH isconstitutively expressed in the mammalian host cell.
 4. The methodaccording to claim 1, wherein the mammalian host cell is a CHO cell. 5.The method according to claim 4, wherein the CHO cell is selected fromthe group consisting of: a CHO-K1, a CHO-DG44 and a CHO-S cell. 6.-7.(canceled)
 8. The method according to claim 1, wherein culturing isperformed in a suspension culture.
 9. The method according to claim 1,wherein culturing is performed in an adherent culture.
 10. The methodaccording to claim 1, wherein the desired recombinant polypeptide is abiosimilar of a recombinant protein.
 11. The method according to claim10, wherein the recombinant protein is selected from the groupconsisting of: Infliximab, Adalimumab, Etanercept, Rituximab,Bevacizumab, Trastuzumab, Ranibizumab, Cetuximab, Erythropoietin alpha,Interferon alpha, Interferon alpha 2a and Interferon alpha 2b.
 12. Themethod according to claim 1, wherein the expression of the hGH ormodified hGH increase cell density and viability of the host mammaliancell compared to a mammalian cell supplemented with insulin-like growthfactor 1 (IGF-1). 13.-14. (canceled)
 15. A recombinant mammalian hostcell for producing a desired recombinant polypeptide, wherein amammalian host cell co-expresses: i) a human Growth Hormone (hGH) ormodified hGH, and ii) a desired recombinant polypeptide, whereinexpression of the hGH or modified hGH enhances survival of the mammalianhost cell and wherein the desired recombinant polypeptide is selectedfrom the group consisting of: Infliximab, Adalimumab, Etanercept,Rituximab, Bevacizumab, Trastuzumab, Ranibizumab, Cetuximab,Erythropoietin alpha, Interferon alpha, Interferon alpha 2a andInterferon alpha 2b.
 16. The recombinant mammalian host cell accordingto claim 15 wherein the hGH is constitutively expressed in the mammalianhost cell.
 17. The recombinant mammalian host cell according to claim15, wherein the mammalian host cell is a CHO cell. 18.-21. (canceled)22. An expression system for producing a desired recombinant polypeptidecomprising: an expression vector comprising a nucleotide sequenceencoding a human Growth Hormone (hGH) or modified hGH; an expressionvector comprising a nucleotide sequence encoding a desired recombinantpolypeptide; and a mammalian host cell used to co-express the hGH ormodified hGH and a desired recombinant polypeptide.
 23. The expressionsystem according to claim 22, wherein the mammalian host cell is a CHOcell.
 24. The expression system according to claim 23, wherein the CHOcell is selected from the group consisting of: a CHO-K1, a CHO-DG44 anda CHO-S cell.
 25. The expression system according to claim 24, whereinthe CHO cell has a dihydrofolate reductase (DHFR) deficiency. 26.-28.(canceled)
 29. The expression system according to claim 22, wherein thedesired recombinant polypeptide is a biosimilar of a recombinantprotein.
 30. The expression system according to claim 29, wherein therecombinant protein is selected from the group consisting of:Infliximab, Adalimumab, Etanercept, Rituximab, Bevacizumab, Trastuzumab,Ranibizumab, Cetuximab, Erythropoietin alpha, Interferon alpha,Interferon alpha 2a and Interferon alpha 2b.
 31. The expression systemof claim 29, wherein the recombinant protein is selected from the groupconsisting of: an antibody that binds tumour necrosis factor, anantibody that binds to a vascular endothelial growth factor, an antibodythat binds to HER2, and an antibody that binds to an epidermal growthfactor receptor. 32.-34. (canceled)